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1426Objectives: Atrial fibrillation (AF) is associated with less favorable outcomes in patients undergoing mitral
valve and tricuspid valve surgery. Despite growing evidence on the potential benefits of surgical ablation for
AF there is significant variability among surgeons in treatment of AF. The purpose of our study was to assess
the effect of the Cox-maze procedure on operative and follow-up outcomes.
Methods: In our prospective study, patients who underwent isolated mitral valve or mitral valveþtricuspid valve
surgery without history of AF (n ¼ 506), with untreated AF (n ¼ 75), or with Cox-maze procedure (n ¼ 236)
were included (N ¼ 817). Sinus rhythm was captured according to Heart Rhythm Society guidelines.
Patients who underwent the Cox-maze procedure were propensity score matched to patients without history
of AF resulting in 208 pairs of patients.
Results:Operative outcomes were comparable after propensity score matching (Cox-maze procedure vs no AF)
stroke/transient ischemic attack (0.5% vs 0.5%; P¼ 1.00), renal failure (2.9% vs 1.4%; P¼ .34), and operative
mortality (1.4% vs 1.4%; P ¼ 1.00). High return to sinus rhythm was documented at 6, 12, and 24 months
(92%, 91%, and 86%, respectively) as well as sinus rhythm off antiarrhythmic drugs (79%, 84%, and
82%, respectively). Incidence of embolic stroke in patients who underwent Cox-maze procedure was 1.7%
(4 out of 232 patients) and 5.1 cases per 1000 person-years. No difference in 4-year cumulative survival between
propensity score-matched groups (91.9% vs 86.9%; log rank, 1.67; P ¼ .20), but higher for patients who
underwent Cox-maze procedure versus patients with untreated AF (hazard ratio, 2.47; P ¼ .048). Higher
additive European System for Cardiac Operative Risk Evaluation (odds ratio, 1.40; P< .001) and limited
surgeon experience with Cox-maze procedure (odds ratio, 3.60; P<.001) were significant predictors for failure
to perform Cox-maze procedure.
Conclusions: In our center, 76% of patients undergoing mitral valve or mitral valveþtricuspid valve surgery
experiencing AF underwent concomitant Cox-maze procedure, which is considerably higher than the national
average. No increased morbidity was associated with the Cox-maze procedure with the benefit of very low
thromboembolic rate. These results suggest the need for performance-based education for AF surgical ablation
to achieve optimal outcomes. (J Thorac Cardiovasc Surg 2013;146:1426-35)The prevalence of degenerative valve disease has increased
during the past 20 years, namely aortic stenosis and mitral
regurgitation. The increase in the prevalence of degenera-
tive valvular disease is attributed to the current longevity
of life—older age is significantly associated with the
development of both aortic stenosis and mitral regurgitation
necessitating surgical repair or replacement.1
In addition, approximately 40% to 50% of patients
undergoing mitral valve (MV) surgery have significant
history of atrial fibrillation.1-3 These patients will usuallye Inova Heart and Vascular Institute, Falls Church, Va.
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The Journal of Thoracic and Cardiovascular Surremain in atrial fibrillation with low rates of conversion to
sinus rhythm following a successful MV surgery if a
surgical ablation procedure is not performed.4-6
The significance of not treating atrial fibrillation at the
time of surgery is that these patients have been found to
have less favorable early and late outcomes following their
MV surgery with or without tricuspid valve (TV) surgery.6-8
Atrial fibrillation has also been found to be an independent,
significant predictor for long-term mortality.9 The potential
benefits as well as the safety and efficacy of a surgical abla-
tion procedure for atrial fibrillation during MV operations
are well documented. However, there is a notable variability
among surgeons inwhether or not to perform an ablation pro-
cedure and how the procedure should be performed.8,10,11
The purpose of our study was to determine the effect of
the Cox-maze III/IV procedure performed in conjunction
with MV or MVþTV surgery on outcomes as well as
determine the variables associated with nonperformance
of the Cox-maze procedure for patients presenting with
atrial fibrillation.gery c December 2013
Abbreviations and Acronyms
EuroSCORE ¼ Eurpean System for Cardiac
Operative Risk Evaluation
HRQL ¼ health-related quality of life
MV ¼ mitral valve
NSR ¼ normal sinus rhythm
PSM ¼ propensity score matching
TV ¼ tricuspid valve
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This was a single-center cohort study in which all data were collected
prospectively for surgery occurring between January 2005 and January
2013. This study was approved by the institutional review board (Nos.
06.022 and 06.037) with patient consent waived. Patients who underwent
an MV procedure with or without a TV procedure were examined
(N¼ 817). Patients were divided into 3 groups based on presence and man-
agement of atrial fibrillation, including: patients without a history of atrial
fibrillation; that is, normal sinus rhythm (NSR) (n ¼ 506), patients with a
history of atrial fibrillation and a concomitant Cox-maze procedure for
atrial fibrillation (n ¼ 236), and patients with a history of atrial fibrillation
not addressed during MV surgery (ie, untreated atrial fibrillation) (n¼ 75).
History of preoperative atrial fibrillation was determined through our local
Society of Thoracic Surgeons database and type of atrial fibrillation was
determined according to Heart Rhythm Society guidelines.
Detailed follow-up data was collected for patients undergoing
Cox-maze procedure as part of our unique atrial fibrillation registry
through mailed surveys and medical record review (mean follow-up,
40.2 28.1 months). Rhythm status for patients who underwent a surgical
ablation procedure was determined according to the Heart Rhythm Society
guidelines and verified by electrocardiogram and 24-hour Holter monitor at
the time points of 6, 12, and 24 months and then yearly thereafter. The
Heart Rhythm Society definition of success (ie, all documented atrial
arrhythmias>30 seconds are considered a failure) was used to determine
the return to sinus rhythm rate at 6, 12, and 24 months.12 Anticoagulation
status was also collected at the follow-up time points and the clinical
indication was determined (ie, history of a clotting disorder, deep vein
thrombosis, pulmonary emboli, mechanical valves, and continual atrial
arrhythmia) or not clinically indicated (ie, no indications for anticoagula-
tion). All patients were followed and treated using our follow-up atrial
arrhythmia control protocol.13 In addition, all patients who were reported
to be in sinus rhythm off antiarrhythmic drugs without a pacemaker
were offered 5- to 7-day mobile cardiac outpatient telemetry monitoring
(CardioNet Inc, Conshohocken, Pa) at 6 and 24 months.
Patients with untreated atrial fibrillation (mean follow-up 35.3  27.1
months) and without history of atrial fibrillation (mean follow-up 42.7 
29.4 months) were followed prospectively for health-related quality of
life through mailed surveys and survival postdischarge through the Social
Security Death Index and National Death Index. Data from the Society of
Thoracic Surgeons was available on all patients as well and definitions
from this database were used for history of atrial fibrillation, preoperative
characteristics, and perioperative outcomes.
Operative Approach
Multiple surgeons performed the complete Cox-maze III/IV lesion set
in all patients, as described previously.14,15 The energy source used was
cryothermia only (Medtronic, Minneapolis, Minn) in 65% of patients
and combination of cryothermia and bipolar radiofrequency (AtriCure
Inc, West Chester, Ohio) in 35% of patients. The left atrial appendage
was amputated and then oversewn in the midsternotomy patients.The Journal of Thoracic and CarHowever, in the minimally invasive procedure, the left atrial appendage
was excluded by endocardial suturing.
Health-Related Quality of Life (HRQL)
HRQL was evaluated at baseline and follow-up using the Short-Form
12. This is a reliable and well-validated instrument for use across diverse
disease populations, including cardiac surgery patients, and is easy to
administer being particularly adept for use in self-report situations.16 A
higher score indicates better HRQL and can be compared against age group
norms. To capture patient perception of atrial fibrillation symptoms, we
administered the Atrial Fibrillation Symptom Checklist: Frequency and
Severity (version 3) to Cox-maze patients.17 This survey consists of 16
symptom items. Higher scores indicate more atrial fibrillation symptoms
and a higher degree of severity when experiencing the symptom.
Statistical Analysis
Continuous data are presented as mean  standard deviation and cate-
gorical data are presented as frequency (percent) unless otherwise noted.
Patient groups were compared using c2 or Fisher exact test for preoperative
and postoperative categorical variables and Student independent samples
t test orMann-WhitneyU test for continuousmeasures as appropriate based
on parametric test assumptions. Statistical significance was considered
P < .05, 2-tailed. All analyses were conducted using SPSS version
17.0 (SPSS Inc, Chicago, Ill) or R version 2.10.1 (The R Foundation for
Statistical Computing).
In an effort to simulate randomization in this observational study, pro-
pensity score matching was conducted between the group without history
of atrial fibrillation and the group with concomitant Cox-maze for atrial
fibrillation. The main purpose of these analyses was to examine if the addi-
tion of the Cox-maze procedure could allow patients with preoperative
atrial fibrillation to experience comparable outcomes as similar patients
without a history of atrial fibrillation. Propensity score matching (PSM)
was conducted using the MatchIt package within R to improve covariate
balance between the 2 groups. Propensity score was estimated via logistic
model and matched between the groups within a caliper of 0.25 propensity
score standard deviations. The covariates used to create the propensity
score were based on clinical relevance and sample characteristics,
including age, gender, diabetes, hypertension, congestive heart failure,
elective status, chronic pulmonary disease, ejection fraction (%), additive
European System for Cardiac Operative Risk Evaluation (EuroSCORE) I,
previous cardiac surgery, and preoperative creatinine level. After matching,
covariate balance was improved for all factors (Figure 1) and the sample
remaining included 416 patients (208 pairs), which was used for all ana-
lyses described as matched or PSM.
Kaplan-Meier analysis was used to compare the 2 matched groups on
4-year cumulative survival. Additionally, unmatched Cox-maze patients
(n ¼ 236) and the subset of patients with untreated atrial fibrillation
(n¼ 75) were compared via Kaplan-Meier analysis to determine if any dif-
ferences in 4-year cumulative survival existed between these 2 groups with
history of atrial fibrillation. Subsequently, multivariate Cox proportional
hazards regression analysis was conducted with the Cox-maze and un-
treated atrial fibrillation groups to determine predictors of 4-year survival,
including age, gender, ejection fraction, hypertension, peripheral vascular
disease, congestive heart failure, chronic pulmonary disease, diabetes,
tricuspid valve procedure (yes or no), cardiopulmonary bypass time, and
surgery groups.
In the Cox-maze group, return to sinus rhythm, incidence of embolic
stroke, and anticoagulation treatment were assessed via descriptive statis-
tics. Also, predictors for atrial fibrillation at 6, 12, and 24 months following
the Cox-maze were evaluated via multivariate logistic regression,
including: age, gender, ejection fraction, additive EuroSCORE, previous
cardioversion or catheter ablation, left atrial size (in centimeters), and dura-
tion of atrial fibrillation before surgery (in years). Changes in HRQL and
atrial fibrillation symptom burden from pre- to post-surgery were evaluateddiovascular Surgery c Volume 146, Number 6 1427
FIGURE 1. Jitter plot illustrating balance achieved from propensity score
matching the treatment (Cox-maze procedure) and control (normal sinus
rhythm) groups.
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and HRQL norms were evaluated via independent samples t tests. Lastly,
exploratory multivariate logistic regression was conducted to determine
the significant predictors for failure to perform a concomitant Cox-maze
procedure. This analysis utilized only unmatched patients with a history
of atrial fibrillation, Cox-maze procedure (yes or no) served as the depen-
dent variable, and independent variables included age, gender, additive
EuroSCORE, diabetes, congestive heart failure, chronic pulmonary dis-
ease, emergent status, and surgeon experience (50 surgical ablation for
atrial fibrillation cases vs<50 surgical ablation for atrial fibrillation cases).RESULTS
Patient Characteristics
Patients presenting to surgery with atrial fibrillation were
older (64.4 13.3 years vs 57.4 12.8 years;P<.001), had
lower ejection fraction (54.5%  11.6% vs 59.9% 
8.0%; P<.001), higher additive EuroSCORE (7.0  3.5
vs 4.8  3.1; P<.001), and there was a greater proportion
of women (54% vs 41%; P<.001) compared with patients
who presented to surgery in sinus rhythm. Within the atrial
fibrillation group, patientswho received theCox-mazeproce-
dure were younger (63.6  13.2 years vs 67.1  13.4 years;
P ¼ .049), had higher ejection fraction (55.8%  10.5% vs
50.5% 14.1%;P¼ .003), and lower additive EuroSCORE
(6.1 2.9vs9.8 3.7;P<.001) comparedwith the untreated
atrial fibrillation group. The Cox-maze group did not differ
from the untreated atrial fibrillation group in nonparoxysmal
atrial fibrillation type (85% vs 81%; P ¼ .47), duration of
atrial fibrillation (38.7 62.8months vs 46.8 60.2months;1428 The Journal of Thoracic and Cardiovascular SurP ¼ .44), or left atrial size (5.3  1.0 cm vs 5.0  1.2 cm;
P ¼ .06).
Before matching, compared with patients who presented
to surgery in sinus rhythm, patients with atrial fibrillation
who underwent the Cox-maze procedure were significantly
older (63.6 13.2 years vs 57.4 12.8 years;P<.001), had
lower ejection fraction (55.8%  10.5% vs 59.9% 
8.0%; P< .001) and were more likely to be a woman
(56% vs 41%; P<.001). They also differed on other clin-
ical characteristics (Table 1), such as higher prevalence of
hypertension (61% vs 49%; P ¼ .003), congestive heart
failure (51% vs 29%; P<.001), previous cardiac surgery
(15% vs 9%; P ¼ .01), and higher additive EuroSCORE
I (6.1  2.9 vs 4.8  3.1; P< .001) and EuroSCORE II
(5.0%  6.4% vs 2.5%  5.4%; P< .001). After PSM,
the groups were well matched on preoperative characteris-
tics (Table 1).
In these 2 groups with concomitant TV surgery (n ¼ 112)
only1patient hadTVreplacement. ForMVreplacements, bio-
prosthesis was used in 73% of patients andmechanical valves
were used in 27%of patients. In theCox-mazegroupwithMV
replacements, 50% were indicated for rheumatic heart
disease. In 4 patients the procedure was performed as a redo
with 2 previousMV repairs and 2 previousMV replacements.
Operative Outcomes and Survival
In the study period 76% of patients with history of atrial
fibrillation (236 out of 311 patients) underwent the Cox-
maze combined either with MV surgery alone (164 out of
236 patients; 69%) or together with a TV procedure (72
out of 236 patients; 31%). Operative outcomes of the 3 un-
matched groups of patients are presented in Table 2. There
were no differences between the patients who presented to
surgery with NSR and those who underwent the Cox-maze
procedure on morbidities, although median intensive care
unit stay and total length of stay were significantly longer
in the Cox-maze group (Ps< .001). Compared with the
Cox-maze group, the group with untreated atrial fibrillation
did experiencemore prolonged ventilation (>24 hours; 28%
vs 7%;P<.001), pneumonia (15% vs 3%;P<.001), longer
median length of stay (9 days [interquartile range, 6-15
days] vs 6 days [interquartile range, 5-10 days]; P ¼ .005),
but fewer readmissions within 30 days (4% vs 12%;
P ¼ .048). The majority of readmissions for the Cox-maze
and NSR groups were for pericardial effusion, atrial
arrhythmia, or anticoagulation-related issues. In the
untreated atrial fibrillation group, the indications for
readmission were similar with the majority of patients
admitted for pericardial effusion and atrial arrhythmia.
After propensity score matching (Figure 1), operative
outcomes remained comparable for the matched groups
(Cox-maze vs NSR patients), including stroke/transient
ischemic attack (0.5% vs 0.5%; P ¼ 1.00), prolonged
ventilation>24 hours (8% vs 7%; P ¼ .86), renal failuregery c December 2013
TABLE 1. Preoperative patient characteristics for nonmatched normal sinus rhythm (NSR) and Cox-maze procedure patient groups and
propensity score matched (PSM) NSR and Cox-maze procedure patient groups
Nonmatched MV/TV PSM MV/TV
NSR (n ¼ 506) Cox-maze (n ¼ 236) NSR (n ¼ 208) Cox-maze (n ¼ 208)
Age,* y 57.4  12.8 63.6  13.2 62.0  12.2 62.6  13.4
Female* 207 (41) 132 (56) 115 (55) 112 (54)
Diabetes 43 (8) 19 (8) 17 (8) 17 (8)
Hypertension* 248 (49) 143 (61) 123 (59) 121 (58)
Congestive heart failure* 144 (28) 121 (51) 91 (44) 93 (45)
Ejection fraction,*% 59.9  8.0 55.8  10.5 57.4  8.8 56.7  10.0
Elective status 444 (88) 201 (85) 179 (86) 180 (87)
Previous cerebrovascular accident 31 (6) 17 (7) 14 (7) 14 (7)
Chronic pulmonary disease 65 (13) 35 (15) 28 (14) 28 (14)
Preoperative creatinine level 1.1  0.9 1.0  0.7 1.1  0.5 1.0  0.7
Peripheral vascular disease 19 (4) 13 (6) 13 (6) 9 (4)
Previous cardiac surgery* 44 (9) 35 (15) 35 (17) 28 (14)
MV repair* 390 (77) 151 (64) 142 (68) 135 (65)
MV replacement* 116 (23) 85 (36) 66 (32) 73 (35)
Additive EuroSCORE I* 4.8  3.1 6.1  2.9 6.0  3.3 5.8  2.6
Concomitant TV surgery*,y 40 (8) 72 (31) 20 (10) 60 (29)
Cardiopulmonary bypass time,*,y min 130.9  42.9 173.0  45.1 129.4  45.8 174.1  45.2
Crossclamp time,*,y min 85.0  28.8 107.4  32.7 83.1  29.9 108.4  33.0
EuroSCORE II,*% 2.5  5.4 5.0  6.4 3.8  7.3 4.1  4.1
Data are presented as mean  standard deviation or n (%). MV, Mitral valve; TV, tricuspid valve; PSM, propensity score matched; NSR, normal sinus rhythm; EuroSCORE,
European System for Cardiac Operative Risk Evaluation. *Significant difference in factor between nonmatched NSR and Cox-maze groups (P<.05). ySignificant difference
in factor between matched NSR and Cox-maze groups (P<.05).
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1.4%; P¼ 1.00) (Table 3). The Cox-maze group did have a
significantly longer median intensive care unit stay (47.1
hours [interquartile range, 23.8-85.6 hours] vs 21.2 hours
[interquartile range, 8.5-43.1 hours]; P< .001) and total
length of stay (6 days [interquartile range, 5-10 days] vs 4
days [interquartile range, 3-6 days]; P<.001).
No difference was found in 4-year cumulative survival
between the matched groups (91.9% [Cox-maze] vs
86.9% [NSR]; log rank, 1.67; P ¼ .20) (Figure 2).
Compared with the untreated atrial fibrillation patients,
4-year cumulative survival was significantly higher forTABLE 2. Postoperative morbidity comparison between unmatched pati
[NSR]), patients with concomitant Cox-maze procedure and patients with
NSR (n ¼ 506)
Stroke/transient inschemic attack 3 (0.6)
Perioperative myocardial infarction 0
Prolonged ventilation*,y 33 (7)
Pneumoniay 7 (1.4)
Deep sternal wound infection 0
Postoperative renal failure 6 (1.2)
Renal failure requiring dialysis 3 (0.6)
Reoperation for bleeding 10 (2)
Length of intensive care unit stay,y h 17.9 (9.1-34.6)
Length of stay,y,z d 3 (2-6)
Readmissions within 30 dz 50 (10)
Operative death 5 (1)
Data are presented as n (%) or median (range).NSR, Normal sinus rhythm; AF, atrial fibrilla
untreated AF groups (P<.05). zSignificant difference in factor between nonmatched Cox
The Journal of Thoracic and Carunmatched Cox-maze patients (90.7% vs 78.3%; log
rank, 9.23; P ¼ .002). After multivariate adjustment for
clinical covariates, 4-year survival in the untreated atrial
fibrillation patients remained significantly lower compared
with the Cox-maze group (hazard ratio, 2.47; P ¼ .048)
(Figure 3). The only other significant predictor of survival
in this model was chronic pulmonary disease (hazard ratio,
3.35; P ¼ .005).
In addition, physicalHRQL scores appeared to increase to
a greater extent in the matched Cox-maze group compared
with the matched NSR patients (8-point vs 4-point improve-
ment), although this difference did not reach statisticalents without atrial fibrillation (AF) history (ie, normal sinus rhythm
untreated AF
Cox-maze (n ¼ 236) Untreated AF (n ¼ 75)
1 (0.4) 2 (3)
0 0
17 (7) 21 (28)
7 (3) 11 (15)
0 0
7 (3) 4 (5)
4 (1.7) 2 (2.7)
7 (3) 3 (4)
48 (25-94.8) 62.3 (25-163.5)
6 (5-10) 9 (6-15)
28 (12) 3 (4)
5 (2) 5 (7)
tion. *>24 hours. ySignificant difference in factor between nonmatched Cox-maze and
-maze and NSR groups (P<.05).
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TABLE 3. Early outcomes for matched patients without atrial
fibrillation history (ie, normal sinus rhythm [NSR]) and patients with
concomitant Cox-maze procedure
NSR
(n ¼ 208)
Cox-maze
(n ¼ 208) P-value
Stroke/transient ischemic attack 1 (0.5) 1 (0.5) 1.00
Perioperative myocardial
infarction
0 0 —
Prolonged ventilation* 15 (7) 16 (8) 1.00
Pneumonia 3 (1.4) 7 (3) .34
Deep sternal wound infection 0 0 —
Postoperative renal failure 3 (1.4) 6 (2.9) .50
Renal failure requiring dialysis 2 (1) 4 (2) .69
Reoperation for bleeding 4 (2) 6 (3) .75
Length of intensive care
unit stay,y h
21.2 (8.5-43.1) 47.1 (23.8-85.6) <.001
Length of stay,y d 4 (3-6) 6 (5-10) <.001
Readmissions within 30 d 22 (11) 26 (13) .65
Operative deathz 3 (1.4) 3 (1.4) 1.00
Data are presented as n (%) or median (range). NSR, Normal sinus rhythm. *>24
hours. ySignificant difference in factor between NSR and Cox-maze groups
(P<.05). z30 days.
FIGURE 3. Outcome of the Cox proportional hazards regression demon-
strating 4-year cumulative survival for mitral valve (MV) patients with
atrial fibrillation (AF) who underwent a concomitant Cox-maze procedure
(n ¼ 236) and those who did not (n ¼ 75).M, Months; TV, tricuspid valve.
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matched patients with HRQL data and only 39% observed
power. There was no difference in mental HRQL improve-
ments by matched groups (F ¼ 0.2; P ¼ .63).The Cox-Maze III/IV Group Outcomes
At discharge, 19 patients (8%) had an atrial arrhythmia
(18 with atrial fibrillation and 1 with typical atrial flutter).
Pacemaker for sinus node dysfunction was implanted in
3 patients (1.3%). The return to sinus rhythm was docu-
mented at 6 (92%, 171 out of 185 patients), 12 (91%,
141 out of 155 patients), and 24 months post-surgeryFIGURE 2. Kaplan-Meier survival curves demonstrating 4-year cumula-
tive survival for propensity score-matched patients (n ¼ 416). M, Months;
MV, mitral valve; TV, tricuspid valve; NSR, normal sinus rhythm.
1430 The Journal of Thoracic and Cardiovascular Sur(86%; 85 out of 96 patients). Return to sinus rhythm off
class I/III anti-arrhythmic drugs at 6, 12, and 24 months
was 79% (144 out of 183 patients), 84% (130 out of 155
patients), and 82% (79 out of 96 patients), respectively. Pre-
dictors of atrial fibrillation at 12 months included higher
operative risk and patient complexity, as reflected by the
additive EuroSCORE (odds ratio, 1.31; 95% confidence
interval, 1.004-1.72; P¼ .047) and longer duration of atrial
fibrillation in years (odds ratio, 1.11; 95% confidence inter-
val, 1.02-1.21; P ¼ .02), but not left atrial size (odds ratio,
1.67; 95% confidence interval, 0.89-3.11; P ¼ .11). Only
longer duration of atrial fibrillation in years (odds ratio,
1.25; 95% confidence interval, 1.07-1.46; P ¼ .004) was
a significant predictor of atrial fibrillation at 24 months.
Patients found to be in sinus rhythm and off class
I/III anti-arrhythmic drugs at 6 and 24 months were offered
5- to 7-day rhythmmonitoring with compliance of 60% and
35%, respectively. Return to NSR per 5- to 7-day rhythm
monitoring was 92% at 6 months (72 out of 78 patients)
and 89% at 24 months (25 out of 28 patients).
Ninety-one percent of Cox-maze patients were dis-
charged from the hospital taking warfarin. At 12 months,
25% of patients remained taking warfarin (37 out of 150 pa-
tients) and were taking it for clinical indications unrelated
to atrial arrhythmia (ie, deep vein thrombosis or pulmonary
embolism), including 10 patients with mechanical valves.
In the remaining patients (n ¼ 113), the majority were not
receiving warfarin treatment by 12 months (84%) leaving
only 16% taking warfarin. Although a little more than
90% of this 16% of patients were documented to be in sinus
rhythm, warfarin was not stopped by their cardiologist. In
mean follow-up of 40.2  28.1 months, the incidence of
embolic stroke in Cox-maze patients following dischargegery c December 2013
Ad et al Acquired Cardiovascular Disease
A
C
Dfrom the hospital was very low (1.7%; 4 out of 232 patients;
5.1 cases per 1000 person-years; 0.5% annual stroke risk).
At the time of stroke, 2 patients were taking warfarin and 3
of 4 were in sinus rhythm. In addition, 3 other patients expe-
rienced transient ischemic attack during the same length of
follow-up (1.3%, 3 out of 232 patients; 3.8 cases per 1000
person-years; 0.4% annual transient ischemic attack risk).
At the time of transient ischemic attack, 2 patients were tak-
ing warfarin and all 3 patients were in sinus rhythm.
Baseline and 12 month assessment of HRQL was
completed in 97 patients following Cox-maze procedure
combined with MV with or without TV surgery. Significant
improvement was found in physical HRQL scores from
before surgery to 12 months post-surgery (40.7-48.3;
t ¼ 6.2; P< .001). Baseline physical HRQL scores were
significantly lower than age norms (t ¼ 6.2; P<.001), but
by 12 months these scores reached similar levels to age
norms (t ¼ 1.4; P ¼ .15). Improvement in mental HRQL
scores from before surgery to 12 months post-surgery did
not reach statistical significance (52.0-54.1; t ¼ 1.7;
P ¼ .09). However, 12-month mental HRQL scores signif-
icantly surpassed those of age norms (t ¼ 3.6; P<.001).
Using the Atrial Fibrillation Symptom Checklist revealed
that the frequency of atrial fibrillation-specific symptoms
declined significantly in this group by 12 months (n ¼ 32;
19.7-9.4; t¼5.0; P<.001), as did severity of atrial fibrilla-
tion symptoms (17.1-9.2; t¼4.7;P<.001). Lastly, changes
in atrial fibrillation symptom frequency (r¼0.46;P¼ .01)
and severity (r ¼ 0.47; P ¼ .01) were significantly corre-
lated with changes in physical HRQL score.
Predicting Addition of Cox-Maze Procedure
In MVþTV patients who presented with history of atrial
fibrillation, the multivariate logistic regression model
significantly predicted addition of the Cox-maze procedure
(c2, 114.93; P<.001). In this model, higher additive Euro-
SCORE (odds ratio, 1.40; 95% confidence interval, 1.24-
1.57;P<.001) and limited surgeon experiencewith surgical
ablation for atrial fibrillation at the time of surgery (odds ra-
tio, 3.60; 95% confidence interval, 1.85-7.01; P< .001)
were found to be significant in predicting not performing
the Cox-maze procedure concomitantly with MV and TV
surgery. Each 1-point increase in additive EuroSCORE
was associated with 40% greater odds of not receiving a
Cox-maze procedure. Using the predicted probability
from this model, the area under the curve was 0.86, indi-
cating the model demonstrated a high level of accuracy in
discriminating patients who did and did not receive the
Cox-maze procedure.
DISCUSSION
In our center 76% of patients who had MV or MVþTV
surgeries while experiencing atrial fibrillation underwent a
concomitant Cox-maze procedure performed by multipleThe Journal of Thoracic and Carsurgeons, indicating higher ablation rates compared to reports
from the Society of Thoracic Surgeons.2,18 No increased
morbidity was associated with the addition of the
Cox-maze procedure and excellent survival was achieved
especially when compared with MV patients who did not
have their atrial fibrillation treated.
Our results are comparable to several other reports that
were published. Bogachev-Prokophiev and colleagues19
reported on 47 patients who underwent a bipolar left sided
ablation procedure with either mitral valve repair (n¼ 5) or
replacement (n ¼ 42) and were monitored by a subcutane-
ous continuous monitor. At 12 months they found that
65.2% (n ¼ 30) of patients had no atrial fibrillation,
6.5% (n ¼ 3) of patients had experienced atrial flutter
(1 atypical flutter and 2 typical flutter) and successfully
underwent catheter ablation, and 27.7% (n ¼ 13) experi-
enced atrial fibrillation with a burden>0.5%.
Ghavidel and colleagues20 used nitrous-based cryother-
mia energy on a group (n ¼ 90) who underwent surgical
ablation (n ¼ 65 pulmonary vein isolation; n ¼ 25 biatrial
Cox-maze) at the same time as MV surgery. The investiga-
tors found that 65.5% of patients were in sinus rhythm at 12
months with left atrial size>6 cm as the only predictor of
failure. It was concluded that the use of cryothermia was
safe and cost-effective and added only minimal time to
the surgery (10 minutes for the pulmonary vein isolation
and 20 minutes for the full Cox-maze procedure).
Several studies demonstrated that patientswithMVdisease
and atrial fibrillation who undergo surgical correction of the
valve disease, but not for atrial fibrillation have poorer short-
and long-term outcomes than patients who come to surgery
with MV disease and are in sinus rhythm.21,22 In addition,
atrial fibrillation was found to be an independent significant
predictor for long-term mortality.9 The effect of preoperative
atrial fibrillation on patients undergoing MV, coronary artery
bypass graft, and aortic valve surgery was studied by Ngaage
and colleagues21-23 and it was determined that preoperative
atrial fibrillation was associated with increased morbidity
and decreased survival if not corrected. In our study, we
found that survival up to 4 years for patients following a
concomitant Cox-maze procedure in MVand MVþTV was
comparable to similar patients who did not present to surgery
with history of atrial fibrillation and did not require a Cox-
maze procedure. This finding suggests that by restoring sinus
rhythm in a relatively high number of patients with atrial
fibrillation undergoingMVandTV surgeries survival benefits
may be expected. In addition, the survival of Cox-maze pa-
tients in our sample was significantly improved compared
with patients with untreated atrial fibrillation. Although we
conducted these analyses adjusting for fundamental differ-
ences between the atrial fibrillation groups, it is possible
that selection bias in performing theCox-maze procedure still
influences this finding. Therefore, the true nature of survival
outcomes in surgically treated and untreated atrial fibrillationdiovascular Surgery c Volume 146, Number 6 1431
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addressed through a prospective randomized controlled trial.
The performance of the Cox-maze procedure, the high
rate of sinus rhythm and the elimination of the left atrial
appendage may have an important effect on risk reduction
of thromboembolic and bleeding events. The documented
success rate using the Heart Rhythm Society definitions is
acceptable even when long-term monitoring was used.
Interestingly, the compliance of patients with long-term
monitoring was rather low. The reasons for not wearing a
monitor for 5 to 7 days were associated with added cost
to the patients due to insurance coverage and not wanting
to be bothered for a week by a device with no perceived
benefit or improved outcome.
In our follow-up we found that about 25% of patients had
an indication for anticoagulation treatment unrelated to
atrial arrhythmia. These findings are not surprising; how-
ever, it should be emphasized that the Cox-maze procedure
is still warranted for these patients due to the expected
improved survival and decreased risk of thromboembolic
events.4,7-9 In our study, we found that for Cox-maze
patients, 91% were discharged from the hospital taking
warfarin, but by 12 months following the Cox-maze sur-
gery, the majority (84%) of patients eligible to be off anti-
coagulation treatment had stopped taking anticoagulants.
The stroke rate found for patients after the Cox-maze proce-
dure (5.1 cases per 1000 person-years) was comparable to
other surgical ablation centers. The rate was also lower
than would be expected when calculated using data
provided by the National Registry of Atrial Fibrillation
(34.5 cases per 1000 person-years), adjusted for distribution
of CHADS score in our sample.24-26 These findings are
encouraging indicating that treatment with anticoagulation
may beminimized safely following theCox-maze procedure
without increasing the risk of stroke or associated mortality,
remaining consistent with our previous findings.27,28
We are pleased by the findings that suggest improved
quality of life and reduced symptoms related to atrial
fibrillation following the Cox-maze procedure. The assess-
ment of quality of life is challenging, especially in this
subgroup of patients who underwent a concomitant surgical
procedure due to significantMVdisease.A large part of their
improvement in quality of life can be attributed to improved
physiology related to valve surgery. In an attempt to improve
our understanding regarding the potential effect of sinus
rhythm restoration on quality of life, we used 2 different
tools to measure the effect: the general Short Form-12 tool
and an atrial fibrillation-specific tool to measure the
frequency and severity of atrial fibrillation-related symp-
toms. Our findings suggest an improvement in the physical
composite score of HRQL, which increased significantly
by 12months, reaching age group norms andwas correlated
with specific atrial fibrillation symptom-related reduction.
Part of this improvement is no doubt related to functional1432 The Journal of Thoracic and Cardiovascular Surimprovement as a result of their concomitant valve proce-
dure(s). However, the high return to sinus rhythm rate by
12 months may also contribute to the influence on physical
composite score of HRQL. In fact, in several recent
publications, the return to sinus rhythm rate for patients
in atrial fibrillation conveyed a significant increase in
their quality of life similar to what was observed in our
study.29-31 This is further supported by the results
captured using an atrial fibrillation-specific questionnaire,
which showed a significant decrease in symptoms associa-
ted with atrial fibrillation and corroborated the assertion
that part of the increase in physical HRQL could be related
to restoration of sinus rhythm.
Grigioni and colleagues32 determined that the risk to
develop atrial fibrillation is about 15% to 21% over 5 years
if conservative treatment is used to manage patients with
functional MV disease and by 10 years 42% to 54% had
developed atrial fibrillation. Moreover, atrial fibrillation
was associated with high risk for cardiac death or heart
failure (adjusted risk ratio, 2.23; P ¼ .025) with the risk
of atrial fibrillation increasing with age and left atrial size.
The authors concluded that the clinical management of
mitral regurgitation should take into account these factors
and interventions should be directed to minimize the
long-term consequences of untreated MV disease. Their
findings together with the findings reported here are impor-
tant when discussing with surgeons the negative effect of
untreated atrial fibrillation following surgery and assists in
advocating for performance-based education for more cen-
ters to be able to offer surgical ablation of atrial fibrillation
when undergoing open heart surgery and especially MVor
MVþTV surgery to achieve optimal outcomes. Interest-
ingly, patient risk and low surgeon experience were found
to be significantly associated with not ablating atrial fibril-
lation in our study. Despite supportive evidence related to
the potential benefit of surgical ablation for atrial fibrillation
during MV surgery, the decision whether or not to perform
the procedure is complex and dependent on surgeon experi-
ence and perception regarding the importance of atrial
fibrillation. Several recent articles have investigated the suc-
cessful use of simulation training in obtaining proficiency
in certain surgical procedures.33-35 Simulation training in
addition to sponsored fellowships in electrophysiology
may be an avenue that can be developed to offer more
opportunities for learning in a safe and economical way
that will help expand centers that offer atrial fibrillation
ablation surgery and improve patient outcomes and
survival. National organizations such as the Heart Rhythm
Society and the Society of Thoracic Surgeons may be well
positioned to help lead this endeavor. We should develop a
decision-making algorithm to optimize patient outcomes
and address different aspects of atrial fibrillation from the
control of the left atrial appendage to the full Cox-maze
procedure.gery c December 2013
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This study was conducted at a very large volume cardiac
surgical institute that performs more than 100 surgical
ablation procedures and 400 valve surgeries annually and
several surgeons have more than 50 cases of surgical abla-
tion experience. Therefore, these results may not be gener-
alizable to smaller volume centers without further training.
Data regarding rhythm and stroke/bleed events following
surgery was only collected in the atrial fibrillation patients
treated with the Cox-maze procedure. Although sinus rhythm
wasmaintained in 86% of patients up to 24months following
surgery, without a comparison to the rhythm status of patients
with untreated atrial fibrillation it is unclear fromour analyses
howmuch lower the expected return to sinus rhythmmight be
without the Cox-maze intervention. In addition, due to small
sample size within the untreated atrial fibrillation group, the
multivariate analyses should be viewed as exploratory
analyses intended to prompt further research regarding these
issues.
CONCLUSIONS
We conclude that patients who undergo MVor MVþTV
surgery along with the Cox-maze procedure for atrial fibril-
lation can expect to have a high rate of return to sinus
rhythm and similar survival compared with patients who
undergo MVor MVþTV surgery in sinus rhythm. Attention
should be directed toward addressing a patient’s atrial fibril-
lation at the same time as his or her valve disease to improve
patient outcomes. However, further educational opportu-
nities through performance-enhanced training must be
made available to surgeons so that patients will have access
to this mode of atrial fibrillation treatment and associated
outcomes.
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Dr Vinay Badhwar (Pittsburgh, Pa). This is another fine
contribution to guide surgical decision making when faced with
atrial fibrillation (AF) at the time of mitral valve operations.
This retrospective analysis of prospectively collected data of 208
propensity-matched pairs of patients receiving mitral surgery
and the Cox-MAZE IV procedure when AF was present versus
mitral surgery alone when it was not. This important work pro-
vides us with clear level II(a) evidence that the addition of a
concomitant Cox-maze IV procedure during mitral surgery is
safe and not associated with any negative effect on short- or
midterm outcomes.
Consistent with the recent literature, this study’s Cox propor-
tional hazards regression comparison of 236 unmatched patients
with AF presenting for mitral surgery who received the maze
procedure versus 75 who did not, also confirms clear short- and
midterm survival advantage associated with the maze operation.
I have 3 questions to help us interpret this important data, which
I will ask in sequence giving you time to respond.
Number 1: In the 75 patients with AFwho did not undergomaze
procedure, how many of these were nonparoxysmal?
Dr Niv Ad (Falls Church, Va). That is an excellent question.
Two groups of untreated and treated patients actually came, the
same distribution of the type of AF.
Dr Badhwar. Number 2: These 75 patients were actually older,
had lower ejection fractions, and a higher preoperative risk profile
as measured by European System for Cardiac Operative Risk Eval-
uation (EuroSCORE). Given the cohort size difference in the maze
versus no maze regression analyses, bias included, how do you
reconcile the influence of preoperative risk on the interpretation
of the Kaplan-Meier survival curves? In other words, tomorrow
when we are faced with an elderly high-risk patient with a low
ejection fraction presenting for mitral surgery, are you convinced
that this data provides us the support that the addition of a maze
operation at the time of mitral replacement or repair is warranted?
Dr Ad. Well, that sums everything. It is the decision making.
We are working a lot on understanding decision making related
to surgical ablation of AF. We created a clinical algorithm of
risk scores combined with surgeon’s experience in surgical abla-
tion to test and better understand what influences the decision
the most. An upcoming publication will cover this.
To put it simply, what type of concomitant problem the patient
has and how sick the patient is. In other words, what do we think in
our ownminds that the 5-year survival of the patient is going to be?
Also, how complex is the surgery going to be if we add the surgical
ablation procedure? In other words, how long does it take you to
add the maze procedure to a mitral valve replacement or repair
(it doesn’t take long if you are doing it a lot)? I am looking all1434 The Journal of Thoracic and Cardiovascular Surthe time at right ventricle function. If the right ventricle is rela-
tively dysfunctional, then my threshold to perform the procedure
is going to be very low.
Dr Badhwar.We know that the effective technical performance
of the Cox-maze IVoperation relies on one’s knowledge of energy
sources and the lesion set; in other words, experience. So as a maze
procedure expert in your institution, what proportion of those 311
cases presenting for mitral surgery with AF did you do person-
ally—approximately 76%? Expecting my hypothesis might be
close, perhaps this is simply a provocative way of asking what
role our professional societies and the device industry should
play in surgical education of the maze procedure now that global
evidence continues to mount as to longitudinal outcome benefits
associated with concomitant surgical ablation?
Dr Ad. I think it is an excellent point, but I think the biggest
question is not my personal contribution to this series. I can give
you the numbers: I did 175 out of 236 ablations and only 4 out
of 75 in the untreated group. Clearly I am more aggressive in
applying the maze procedure in my patients.
I believe that the biggest message is how can someone with
more experience within a group of surgeons—and this applies to
any type of surgery not just for AF—can convey a solid message
to their other partners. There are 2 different types of surgeons:
those who are more experienced than you are and they know and
have seen everything before you and, therefore, it is very difficult
to change them, and those who are younger and reluctant to
increase the complexity of the procedure and by so doing may in-
crease morbidity.
My role right now is to convey a message that it is safe and can
be done appropriately, it can be staged, and maybe I can assist
them in part of the cases so younger surgeons—as well as more
veteran ones who are willing to learn—are shown how to do it
appropriately and will apply the procedure to many more eligible
patients.
Dr Badhwar. So that this data provides us with a call to action
to further promote surgical education of surgical ablation?
Dr Ad. Yes.
Dr Patrick M. McCarthy (Chicago, Ill). I have some short,
specific questions. How did you handle the left atrial appendage
in the 2 groups, and do you know the late stroke risk in the groups?
DrAd. For the open cases, until recently (I don’t have the cutoff
dates) I think in a little more than 210 patients the appendage was
basically cut and oversewn. There are not any other devices. Lately
we started to use with much success the AtriClip (AtriCure, Inc,
West Chester, Ohio), which we are very happy with. These are
the 2 major modes.
As for the AF group, unfortunately, and this is something we are
working hard on, only in 4 out of 75 patients the appendage was
managed. This is a gap that we have to close, and I think that
now it is clear that no patients with AF, whether they have AF sur-
gery or not, should leave the operating room with the left atrial
appendage not being closed. We don’t have the data about the
late stroke rate for the untreated group.
DrMcCarthy.Another quick question: How do you handle dis-
continuing warfarin and do you use scores like CHADS, or CHA2
DS2 VASc to help decide?
DrAd.We put all patients, unless there is a contraindication, on
warfarin. Our time to stop warfarin is 6 months, because I thinkgery c December 2013
Ad et al Acquired Cardiovascular Diseasethere is a lot of background noise around 3months, and if you try to
stop it at 3 months it is kind of unrealistic. Patients’ antiarrhythmia
drugs are being stopped at 3 months if they are in sinus rhythm, and
they are being monitored at 6 months, and if the patients are found
to be in sinus rhythm, we perform echocardiography, and if the
appendage is eliminated and there is no smoke in the left atrium,
in other words, the flow seems to be okay regardless of A-waves
in the left atrium, we stop the warfarin. We don’t really look
into the CHADS score, and we actually published an excellent
article a while back that showed that the CHADS score is irrelevant
in this subgroup of patients.
Dr A. Marc Gillinov (Cleveland, Ohio). Everybody in this se-
ries had a biatrial lesion set, a Cox-maze III or IV. What would you
say to the surgeonwho says, okay, I am going to perform ablations,
but I am only going to do pulmonary vein isolation?
Dr Ad. I don’t think it’s a good idea, even in the paroxysmal
setup, because we don’t know enough about the effects of parox-
ysmal AF on the other parts of the atrium; for example, can it beThe Journal of Thoracic and Caroriginated outside the pulmonary veins or not? We know it’s a
long discussion. So I would definitely recommend considering
the biatrial Cox-maze lesion set in all patients unless there are is-
sues that should be dealt with to avoid it.
Dr Harold G. Roberts (Lauderdale Lakes, Fla). Were any of
the failures perhaps related to assessment of left atrial size?
Have you found that if you do have a large left atrium that reduc-
tion has any role in increasing the success?
Dr Ad. In our multivariate models we never found atrial size as
an independent predictor in a multivariate model for failure. The
only predictor for failure in our multivariate model that is consis-
tent is duration of AF before surgery. There is a slight decrease in
success rate as you go into the larger size of atrium, but 16% of pa-
tients had left atrial size>6 cm. So we are not talking about giant
atria. I don’t think we have enough evidence to support left atrial
reduction, we don’t have time to discuss it here, but I am not doing
left atrium reduction surgery besides cutting out the left atrial
appendage.diovascular Surgery c Volume 146, Number 6 1435
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